Prosecution Insights
Last updated: November 20, 2026
Application No. 19/548,088

METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST

Non-Final OA §DOUBLEPATENT
Filed
Feb 24, 2026
Priority
Feb 21, 2014 — provisional 61/943,019 +5 more
Examiner
CHATTIN, AMY MARIE
Art Unit
1643
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Regeneron Pharmaceuticals Inc.
OA Round
1 (Non-Final)
71%
Grant Probability
Favorable
1-2
OA Rounds
3y 0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 71% — above average
71%
Career Allowance Rate
40 granted / 56 resolved
+11.4% vs TC avg
Strong +46% interview lift
Without
With
+45.9%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
46 currently pending
Career history
104
Total Applications
across all art units

Statute-Specific Performance

§101
3.8%
-36.2% vs TC avg
§103
32.1%
-7.9% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
32.4%
-7.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 56 resolved cases

Office Action

§DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims Status The Amendment filed on 24Feb2026 is acknowledged in which claim(s) 1-314 were canceled, and claim(s) 315-326 are new. Claim(s) 315-326 is/are currently pending and presented for examination on the merits. Specification The disclosure is objected to because of the following informalities: The paragraph numbers (e.g., [0001], [00294]) should have a consistent number of digits. The paragraph numbers end with “[00294]” on page 70 of the specification. However, there are 132 pages in the instant specification. Unnumbered paragraphs on pages 70-132 should have paragraph numbers added. Appropriate correction is required. Claim Interpretation Claim(s) 315-326, recite “a background therapy comprising…ICS…” in lines 1-2 of claim 315. The instant specification states “…the mandatory background therapy, ICS/LABA combination product, as defined as: 80% of total number of prescribed "stable dose" puffs taken during the screening period…” [e.g., pg. 83, ¶ 2], and “…a Screening Period (14 to 21 days)…” [e.g., pg. 72, ¶ 1]. The total number of puffs prescribed is not specifically defined in the instant disclosure (e.g., the total number of puffs prescribed could be “1” in the screening period). The broadest reasonable interpretation (BRI) is considered to include any moderate to severe asthma subject on background therapy comprising ICS (e.g., ICS inhaler) prior to dupilumab administration. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claim(s) 315-326 is/are rejected on the ground of nonstatutory double patenting as being unpatentable over claim(s) 1-7, 25-28 of U.S. Patent No. 12,685,771 B2 (hereinafter “US771”). Although the claims at issue are not identical, they are not patentably distinct from each other. Regarding instant claim(s) 315-320, US771 claims 1-3, 25 teach a method of add-on maintenance for treating moderate to severe asthma in a subject in need thereof comprising 600 mg dupilumab and one or more secondary doses of 300 mg of dupilumab. US771 claim 4 teaches the one or more secondary doses are administered every other week (q2w); claim 5 teaches that the one or more secondary doses are administered for at least 24 weeks; claim 6 teaches the administration is subcutaneous; and claim 7 teaches the subject has a blood eosinophil count of greater than or equal to 300 cells/μL. Instant claimed methods are considered to be a species of the broader genus of methods disclosed by US771. Per MPEP 2131.02(I) “A species will anticipate a claim to a genus”. Regarding instant claim(s) 321-326, US771 claims 26-28 teaches a method for add-on maintenance treatment of moderate to sever asthma in a subject in need thereof, comprising administering to the subject by subcutaneous injection an initial dose of 400 mg of dupilumab, and one or more secondary doses of 200 mg of dupilumab administered every other week (q2w), and wherein the subject has an eosinophilic phenotype. Instant claimed methods are considered to be a species of the broader genus of methods disclosed by US771. Per MPEP 2131.02(I) “A species will anticipate a claim to a genus”. Claim(s) 315-326 is/are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claim 315-316, 319, 321, 327, 329-330, 333-337, 339-344 of copending Application No. 19/548,022 (effective filing date: 15Sep2014, referencing claim set filed 24Feb2026; hereinafter “A022”). Although the claims at issue are not identical, they are not patentably distinct from each other. Regarding instant claim(s) 315-320, A022 claim 315 teaches a method for treating moderate to severe asthma in a subject in need thereof comprising administering to the subject as an add-on maintenance treatment an initial dose of above 600 mg of dupilumab, followed by one or more secondary does administered of about 300 mg of the dupilumab every other week (q2w). A022 claim 316 teaches the subject has a baseline blood eosinophil level of at least 300 cells/μL; claim 319 teaches the subject has moderate persistent asthma; claim 320 teaches the subject has severe persistent asthma and claim 327 teaches a method for treating moderate to severe asthma in a subject with baseline blood eosinophil level of at least 300 cells/μL, comprising administering to the subject as an add-on maintenance treatment an initial dose of about 600 mg of dupilumab, followed by one or more secondary doses of about 300 mg of dupilumab administered every other week (q2w). While not identical, the instant claimed methods are considered to be a species of the broader genus of methods disclosed by A022. Per MPEP 2131.02(I) “A species will anticipate a claim to a genus”. Additionally, regarding instant claim(s) 315-320, A022 claim 333 is identical in wording to instant claim 315; claim 334 teaches the background therapy further comprises a LABA; claim 335 teaches secondary doses are administered for at least 24 weeks; claim 336 teaches the subject achieves an improvement from baseline in AQLQ score; claim 337 teaches the subject has moderate persistent asthma; and claim 338 teaches the subject has severe persistent asthma. Regarding instant claim(s) 321-326, A022 claim 321 teaches a method for treating moderate to severe asthma in a subject in need thereof comprising administering to the subject as an add-on maintenance treatment an initial dose of above 400 mg of dupilumab, followed by one or more secondary does administered of about 200 mg of the dupilumab every other week (q2w); claim 329 teaches a method for treating moderate to severe asthma in a subject comprising administering to the subject as an add-on maintenance treatment an initial dose of about 400 mg of dupilumab, followed by one or more secondary doses of about 200 mg of the dupilumab administered every other week (q2w); and claim 330 teaches the subject has a baseline blood eosinophil level of at least 300 cells/μL. While the limitations are not identical, the instant claimed methods are considered to be a species of the broader genus of methods disclosed by A022. Per MPEP 2131.02(I) “A species will anticipate a claim to a genus”. Additionally, regarding instant claim(s) 321-326, A022 claim 339 is identical in wording to instant claim; claim 340 teaches the background therapy further comprises a LABA; claim 341 teaches the secondary doses are administered for at least 24 weeks; claim 342 teaches the subject achieves an improvement from baseline in AQLQ score; claims 343 teaches the subject has moderate persistent asthma; and claim 344 teaches the subject has severe persistent asthma. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Claim(s) 315-326 is/are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-4, 8, 19, 24-26 of copending Application No. 19/558,816 (effective filing date: 04May2018, referencing claim set filed 06Mar2026; hereinafter “A816”). Although the claims at issue are not identical, they are not patentably distinct from each other. Regarding instant claim(s) 315-326, A816 claim 1 teaches a method for treating a subject having severe uncontrolled asthma comprising administering to the subject a loading dose of an antibody or antigen binding fragment thereof that specifically binds to IL4R and administering to the subject a plurality of maintenance doses of the antibody or antigen binding fragment thereof; claim 2 teaches the maintenance dose is administered every two weeks (q2w); claim 3 teaches the loading dose is about 600 mg; claim 4 teaches the maintenance dose is about 300 mg; claim 8 teaches the maintenance dose is administered for at least 24 weeks; claim 19 teaches the subject has a blood eosinophil count of greater than about 300 cells/μL; claims 24-26 teach the antibody sequences (e.g., of dupilumab). While the limitations are not identical, the instant claimed methods are considered to be a species of the broader genus of methods disclosed by A816. Per MPEP 2131.02(I) “A species will anticipate a claim to a genus”. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Free From the Prior Art During the course of examination, unexpected results were identified which are considered to render the instant invention nonobvious in view of the closest prior art. Specifically, at the time of filing, Wenzel et al. (N Engl J Med 2013;368:2455-66; hereinafter “Wenzel”) taught methods for treating moderate to severe asthma in subjects with blood eosinophil counts of at least 330 cells/μL who used inhaled corticosteroids (ICS) and long-acting beta-agonists (LABAs), comprising administering an initial dose of 300 mg of dupilumab and one or more secondary doses of 300 mg of dupilumab [e.g., background, methods]. Wenzel further taught subtle improvements in FEV1 results in the dupilumab treatment group versus baseline (e.g., up to approximately 10% at week 12) [e.g., figure 2C], and slight improvements in the morning PEF results of the dupilumab group relative to baseline (e.g., approximately 14 L/min at week 12) [e.g., Table 2]. Wenzel does not teach, nor suggest (1) treating moderate to severe asthma comprising a 600 mg initial dose of dupilumab and one or more secondary doses of 300 mg of dupilumab, (2) treating moderate to severe asthma comprising a 400 mg initial dose of dupilumab and one or more secondary doses of 200 mg of dupilumab, or (3) that either of these methods of treating moderate to severe asthma would result in (a) markedly improved FEV1 results (e.g. up to 18% improvement) compared to baseline at week 12 [e.g., instant disclosure: figs 3-5, 27-28, Tables 15-17 ] or (b) markedly improved morning PEF results compared to baseline at week 12 (e.g., up to 40 L/min or more) [e.g., instant disclosure: fig 42]. Further, there was no rationale in the prior art at the time of filing that would have caused one of ordinary skill in the art to expect such increases in FEV1 and/or morning PEF results in moderate to severe asthma patients treated with either (1) a 600 mg initial dose of dupilumab and one or more secondary doses of 300 mg of dupilumab, or (2) a 400 mg initial dose of dupilumab and one or more secondary doses of 200 mg of dupilumab. Therefore, the FEV1 and morning PEF improvements as a result of treating moderate to severe asthma in a subject on background therapy comprising an inhaled corticosteroid (ICS) comprising (1) a 600 mg initial dose of dupilumab and one or more secondary doses of 300 mg of dupilumab, or (2) a 400 mg initial dose of dupilumab and one or more secondary doses of 200 mg of dupilumab are considered unexpected based on the prior art teachings at the time of filing (see above for details). Conclusion No claims are currently allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AMY M CHATTIN whose telephone number is (571)270-0646. The examiner can normally be reached T-F 0600-1600 PST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Julie Wu can be reached at (571) 272-5205. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /AMY M. CHATTIN/Examiner, Art Unit 1643 /GARY B NICKOL/Primary Examiner, Art Unit 1643
Read full office action

Prosecution Timeline

Feb 24, 2026
Application Filed
Oct 27, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12797452
METHODS TO STIMULATE IMMUNE RESPONSES TO MUTANT RAS USING ANUCLEATE CELLS
3y 9m to grant Granted Nov 17, 2026
Patent 12797415
SYNTHETIC ANTIGENS AS CHIMERIC ANTIGEN RECEPTOR (CAR) LIGANDS AND USES THEREOF
3y 7m to grant Granted Nov 17, 2026
Patent 12799226
IMPROVED ANTIGEN BINDING RECEPTORS
3y 6m to grant Granted Nov 17, 2026
Patent 12782357
ANTIBODIES THAT BIND TO LRP5 PROTEINS AND METHODS OF USE
4y 8m to grant Granted Nov 03, 2026
Patent 12753229
COMPOSITIONS AND METHODS FOR MODULATING FLRT3 MEDIATED SIGNAL TRANSDUCTION
3y 9m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
71%
Grant Probability
99%
With Interview (+45.9%)
3y 9m (~3y 0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 56 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month